Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jun;73(6):2591-2593.
doi: 10.1002/hep.31706. Epub 2021 May 21.

Immune Checkpoint Inhibitors in Combinations for Hepatocellular Carcinoma

Sharanya Maanasi Kalasekar  1 , Ignacio Garrido-Laguna  1   2 , Kimberley Jane Evason  1   3
Affiliations

Immune Checkpoint Inhibitors in Combinations for Hepatocellular Carcinoma

Sharanya Maanasi Kalasekar et al. Hepatology. 2021 Jun.
No abstract available

PubMed Disclaimer

References

    1. Faivre S, Rimassa L, Finn RS. Molecular therapies for HCC: looking outside the box. J Hepatol 2020;72:342-352.
    1. Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med 2020;382:1894-1905.
    1. Cheng AL, Hsu C, Chan SL, Choo SP, Kudo M. Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma. J Hepatol 2020;72:307-319.
    1. Vitale G, Dicitore A, Gentilini D, Cavagnini F. Immunomodulatory effects of VEGF: clinical implications of VEGF-targeted therapy in human cancer. Cancer Biol Ther 2010;9:694-698.
    1. Fukuoka S, Hara H, Takahashi N, Kojima T, Kawazoe A, Asayama M, et al. Regorafenib plus nivolumab in patients with advanced gastric or colorectal cancer: an open-label, dose-escalation, and dose-expansion phase Ib trial (REGONIVO, EPOC1603). J Clin Oncol 2020;38:2053-2061.

MeSH terms

Substances

LinkOut - more resources